Latest news with #LiisaHurme
Yahoo
25-04-2025
- Business
- Yahoo
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS25 April 2025 at 17.20 EEST Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly, indirectly and through financial instruments by BlackRock, Inc. and its funds increased on 24 April 2025 above five (5) per cent of Orion Corporation's total shares. Total positions of BlackRock, Inc. and its funds subject to notification:% of shares and voting rights (total of point A) % of shares and voting rights through financial instruments (total of point B) Total of both in % (points A + B) Total number of shares and voting rights of issuer Resulting situation on the date on which threshold was crossed or reached 5.01% shares Below 5% voting rights 0.00% shares Below 5% voting rights 5.01% shares Below 5% voting rights 141,134,278 shares 763,427,275 voting rights Position of previous notification (if applicable) Below 5% shares Below 5% voting rights Below 5% shares Below 5% voting rights Below 5% shares Below 5% voting rightsNotified details of the resulting situation on the date on which the threshold was crossed: Point A: Shares and voting rights: Class/type of sharesISIN code Number of shares and voting rights % of shares and voting rightsDirect (SMA 9:5) Indirect (SMA 9:6 and 9:7) Direct (SMA 9:5) Indirect (SMA 9:6 and 9:7) FI00090143777,071,241 shares Below 5% voting rights5.01% shares Below 5% voting rights POINT A SUBTOTAL 7,071,241 shares Below 5% voting rights 5.01% shares Below 5% voting rights Point B: Financial instruments according to SMA 9:6a: Type of financial instrument Expiration date Exercise / Conversion Period Physical or cash settlement Number of shares and voting rights % of shares and voting rights American Depositary Receipt (US68628Y1047) N/A N/A Physical 145 shares Below 5% voting rights 0.00% shares Below 5% voting rightsPOINT B SUBTOTAL 145 shares Below 5% voting rights 0.00% shares Below 5% voting rights Orion Corporation Liisa Hurme President and CEO Olli Huotari EVP, Corporate Functions Contact person:Tuukka Hirvonen, Investor Relations, Orion Corporationtel. +358 10 426 2721 Publisher:Orion CorporationCommunicationsOrionintie 1A, FI-02200 Espoo, Orion is a globally operating Finnish pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2024 amounted to EUR 1,542 million and the company had about 3,700 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.
Yahoo
23-04-2025
- Business
- Yahoo
Orion Group Interim Report January–March 2025
ORION CORPORATION INTERIM REPORT 1–3/2025 23 APRIL 2025 at 12:00 EEST Orion Group Interim Report January–March 2025 January–March 2025 Highlights Net sales totalled EUR 354.6 (January–March 2024: 308.5) million Operating profit was EUR 77.9 (56.0) million Basic earnings per share were EUR 0.44 (0.31) Cash flow from operating activities per share was EUR 0.55 (0.78) Outlook for 2025 remains unchanged: Net sales are estimated to be EUR 1,550 million to EUR 1,650 million. Operating profit is estimated to be EUR 350 million to EUR 450 million. Key figures1–3/25 1–3/24 Change % 1–12/24 Net sales, EUR million 354.6 308.5 +14.9% 1,542.4 EBITDA, EUR million 91.5 68.5 +33.6% 509.4 % of net sales 25.8% 22.2% 33.0% Operating profit, EUR million 77.9 56.0 +39.1% 416.6 % of net sales 22.0% 18.2% 27.0% Profit before taxes, EUR million 76.8 54.9 +39.9% 413.1 % of net sales 21.7% 17.8% 26.8% Profit for the period, EUR million 61.3 43.8 +39.9% 329.9 % of net sales 17.3% 14.2% 21.4% Research and development expenses, EUR million 41.0 36.8 +11.3% 179.6 % of net sales 11.6% 11.9% 11.6% Capital expenditure, EUR million 20.5 13.1 +56.7% 86.1 % of net sales 5.8% 4.2% 5.6% Interest-bearing net liabilities, EUR million 61.8 6.4 > 100 % 121.7 Basic earnings per share, EUR 0.44 0.31 +39.8% 2.35 Cash flow from operating activities per share, EUR 0.55 0.78 -29.7% 2.09 Equity ratio, % 62.9% 48.8% 61.9% Gearing, % 5.8% 0.9% 12.1% Return on capital employed (before taxes), % 23.4% 22.8% 34.9% Return on equity (after taxes), % 23.7% 21.9% 34.8% Average number of personnel during the period 3,928 3,673 +7.0% 3,712President and CEO Liisa Hurme: Strong start for the year "In January–March 2025, our net sales increased by 14.9 percent to EUR 354.6 (308.5) million and operating profit increased by 39.1 percent to EUR 77.9 (56.0) million. The year 2025 has started strongly with almost all business divisions reporting good growth. Nubeqa® continued to drive the growth of the Group and the Innovative Medicines business division. Both royalty income and product sales increased significantly from the comparison period. In addition, Nubeqa®'s product sales grew from the previous quarter and were at an all-time high so far. In Branded Products, all therapy areas grew nicely. Starting from this reporting period, we will split the division's net sales by three therapeutic areas. Each therapy area's strategy is to build business around one key product group. In Respiratory, the key product group is Easyhaler® product portfolio, in CNS entacapone products and in Women's Health Divina® series. Generics and Consumer Health and Animal Health business divisions also continued their growth path as expected in the first quarter of 2025. The decline in Fermion's external net sales from the comparison period is explained by the allocation of capacity more to internal use, as well as by timing of deliveries. Operating profit grew again significantly faster than net sales, which is mostly explained by the growth of Nubeqa® royalties and product sales, but also by the good development of the rest of the business. The growth of Nubeqa® royalties was strong, especially considering the fact that, as usual, the previous quarter's product sales, which were very good at the end of 2024, have been deducted from the royalty. Operating expenses increased but were lower than we anticipated. Sales and marketing expenses were increased by, among other things, investments in the promotion of the Easyhaler® product portfolio, as well as the Japanese sales office established last year. The increase in research and development costs is explained by the progress of clinical development projects and the research portfolio, where the costs of biological medicines, in particular, increase significantly as they approach the clinical development stage. US import tariffs continue to be a hot topic worldwide, and there is a lot of uncertainty around the topic right now. The United States is an important market for Orion, and we will, of course, follow the development of the situation closely. In March, we announced that Orion is establishing a new research & development centre in Cambridge, UK during 2025. With this we aim to accelerate our global growth strategy and the development of innovative medicines. The new centre will focus on the pharmaceutical development of new biological and large-molecule therapies. Orion's own clinical development projects progressed as planned during the early part of the year. In addition, we have added to Orion's list of key clinical development projects a Phase 3 project, in which our partner Tenax develops oral levosimendan for the treatment of pulmonary hypertension in heart failure with preserved ejection fraction. Tenax has announced that it will increase the number of patients in the ongoing study and plans to start during 2025 a second phase III study which is aiming for global registration. With these advances, we felt the time was right to include Tenax Phase III projects with levosimendan in Orion's research pipeline. The original license agreement with Tenax (formerly Phyxius) was signed already in 2013. All in all, the year 2025 has started very well and from here it is good to continue this year forward together with all Orionees and numerous partners.' Outlook for 2025 Net sales are estimated to be EUR 1,550 million to EUR 1,650 million. Operating profit is estimated to be EUR 350 million to EUR 450 million. Webcast and Conference Call A webcast and a conference call for analysts, investors and media representatives will be held on Wednesday, 23 April 2025 at 13.30 EEST. A link to the live webcast is available on Orion's website at A recording of the event will be available on the website later the same day. Conference call can be joined by registering through the following link: Phone numbers and the conference ID to access the conference will be provided after the registration. In case you would like to ask a question during the conference, please dial *5 on your telephone keypad to enter the question queue. Questions can also be presented in writing through the question form of the webcast. Upcoming events Capital Markets Day 2025 Thursday 22 May 2025 Half-Year Financial Report January–June 2025 Friday 18 July 2025 Interim Report January–September 2025 Tuesday 28 October 2025 Espoo, 23 April 2025 Board of Directors of Orion Corporation For additional information about the report: Tuukka Hirvonen, Investor Relations, tel. +358 10 426 2721 or +358 50 966 2721 Publisher: Orion Corporation Orion is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. In 2024 Orion's net sales amounted to EUR 1,542 million and the company employed about 3,700 professionals worldwide, dedicated to building well-being. Orion's A and B shares are listed on Nasdaq Helsinki. Attachment Orion Interim Report Q1 2025Sign in to access your portfolio
Yahoo
22-04-2025
- Business
- Yahoo
Invitation to Orion's Capital Markets Day on 22 May 2025
ORION CORPORATION INVESTOR NEWS 22 APRIL 2025 at 9.00 EEST Invitation to Orion's Capital Markets Day on 22 May 2025 Orion invites analysts, institutional investors, bankers and media representatives to its Capital Markets Day on Thursday 22 May 2025. The event will be held at Event Venue Eliel, at Töölönlahdenkatu 2, Helsinki, Finland. During the afternoon, Orion's President & CEO, Liisa Hurme, CFO René Lindell, and other members of the Executive Management Board will discuss Orion's growth strategy, financial objectives and businesses. Attendees will have the opportunity to ask questions during the event. Anyone can follow the event via a live webcast at starting at 13.00 EEST. The recording of the event will be available at the same address shortly after the event. The presentation materials will be available on Orion's website in the morning on 22 May 2025. The language of the event and the materials is English. Participants will have the opportunity to ask questions during the event. Questions can also be submitted via webcast. Agenda of Orion's Capital Markets Day 2025 12:45 EEST Registration 13:00 EEST The event and webcast begins 13:05 EEST Presentations Liisa Hurme, President and CEO Outi Vaarala, Executive Vice President, Innovative Medicines and Research & Development Hao Pan, Executive Vice President, Branded Products Q&ABREAK Satu Ahomäki, Executive Vice President, Generics and Consumer Health Niclas Lindstedt, Executive Vice President, Animal Health René Lindell, CFO Q&A 16:30 EEST Event ends The program is subject to change. A more detailed agenda will be available at: closer to the event. Registration In order to attend the event at the venue, please register at by 15 May 2025 at the latest. The number of seats is limited, and seats will be filled in order of registration. Contact person:Tuukka Hirvonen, Investor Relations, Orion Corporation tel. +358 10 426 2721 Publisher:Orion CorporationCommunicationsOrionintie 1A, FI-02200 Espoo, Orion is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. In 2024 Orion's net sales amounted to EUR 1,542 million and the company employed about 3,700 professionals worldwide, dedicated to building well-being. Orion's A and B shares are listed on Nasdaq in to access your portfolio
Yahoo
11-03-2025
- Business
- Yahoo
Orion Corporation: Managers' transactions
ORION CORPORATION MANAGERS' TRANSACTIONS 11 MARCH 2025 at 09.00 EET Orion Corporation: Managers' transactions – Liisa Hurme Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons. Orion Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: Liisa HurmePosition: Chief Executive OfficerIssuer: Orion OyjLEI: 74370029VAHCXDR7B745Notification type: INITIAL NOTIFICATIONReference number: 99372/4/4 ____________________________________________Transaction date: 2025-03-10Outside a trading venueInstrument type: SHAREISIN: FI0009014377Nature of transaction: RECEIPT OF A SHARE-BASED INCENTIVE Transaction details(1): Volume: 17000 Unit price: 0 EUR Aggregated transactions (1): Volume: 17000 Volume weighted average price: 0 EUR Orion Corporation Liisa HurmePresident and CEO Olli HuotariExecutive Vice President, Corporate Functions Publisher:Orion CorporationCommunicationsOrionintie 1A, FI-02200 Espoo, Finlandhttp:// Orion is a globally operating Finnish pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2024 amounted to EUR 1,542 million and the company had about 3,700 employees at the end of the year. Orion's A and B shares are listed on Nasdaq in to access your portfolio
